Homoharringtonine
A ribosomal inhibitor.
General information
Homoharringtonine is a semisynthetic alkaloid derivate. It is a proteosynthesis inhibitor used for treatment of chronic myeloid leukaemia (ChEBI).
Homoharringtonine on DrugBank
Homoharringtonine on PubChem
Homoharringtonine on Wikipedia
Synonyms
HHT; Omacetaxine mepesuccinate
Marketed as
CEFLATONIN; MYELOSTAT; SYNRIBO
CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Antiviral options against SARS-CoV-2 infection
Preprint Screening |
VERO E6 cell cultures | synergistic effect in combination with the virus-directed drug nelfinavir |
May/12/2020 | |
|
Transcription-based drug repurposing for COVID-19
Small molecule In silico |
in silico | 2.93 | Predicted to inhibit SARS-CoV-2 based on transcriptional response (virus defence-like) profile. |
Sep/25/2020 |
|
Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19
Small molecule In vitro In silico |
in silico; Vero E6 cells; SARS-CoV-2 strain hCoV-19/Taiwan/NTU13/2020 | Cell treatment results in transcriptional response with high degree of similarity to interferon beta treatment. Potently inhibits SARS-CoV-2 infection in vitro (IC50 = 165.7 nM) with selectivity index of 6.7. |
Dec/02/2020 |
